From June 2023, all our podcasts will move to https://lupusbmj.podbean.com.
You can continue with your subscription on your favourite podcast App.

Lupus Science and Medicine is a global, peer reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Lupus Science and Medicine podcast

Duane Peters from the Lupus Foundation of America interviews Professor Eric Morand from Monash University in Australia and Dr Raj Tummala from AstraZeneca in the USA about phase II and III trials of the human monoclonal antibody anifrolumab.

Their pooled analysis of data from the MUSE, TULIP-1 and TULIP-2 trials showed that, in addition to demonstrating efficacy in adults with moderate to severe systemic lupus erythematosus (SLE), anifrolumab was generally well tolerated with an acceptable safety profile. Anifrolumab was associated with an increased incidence of herpes zoster and respiratory tract infections and a lower reported rate of SLE worsening. This positive benefit–risk profile means that anifrolumab is a potential new treatment option for SLE.

Access the paper here: https://lupus.bmj.com/content/8/1/e000464

BMJ Podcast Series

Safety profile of anifrolumab in SLE patients

Selles osas arutleb taskusõbrahnna Kati, et mis on enesekindlus ja kuidas võiks enesekindlaks saada!

Blondcast - 8 / Enesekindlus

Disc2-18

Disc2-12

NKIN D'OSKLOU

IKEYAOUNE

Duane Peters from the Lupus Foundation of America talks to Dr Cristina Drenkard from Emory University and Dr Teresa Brady from Clarity Consulting and Communications, both based in Atlanta, USA. 

They discuss their paper on the relationship between levels of self-efficacy and health behaviours and outcomes in black women with SLE. Their study specifically evaluated the associations between age, educational level and depression in SLE patients and the degree of pain and fatigue they experienced. These findings may help predict who might benefit most from self-efficacy-enhancing interventions to improve quality of life.

Access the article: https://lupus.bmj.com/content/9/1/e000566

Lupus Science and Medicine Podcast Series

What's the relationship between self-efficacy and quality of life in SLE patients?

Duane Peters from the Lupus Foundation of America interviews Professor Ronald van Vollenhoven from the Amsterdam University Medical Centers in the Netherlands and Dr Cynthia Aranow from the Feinstein Institute for Medical Research in New York, USA. 

They discuss the efforts of the DORIS international task force to agree on a single definition of remission in systemic lupus erythematosus, which they hope will ensure that clinicians, patients and researchers in the field are all working towards the same outcome. 

Access the article: https://lupus.bmj.com/content/8/1/e000538

Lupus Science and Medicine podcast series

Defining remission in systemic lupus erythematosus

Duane Peters from the Lupus Foundation of America interviews Dr Peter Izmirly from New York University and Dr Elizabeth Ferucci from the Alaska Native Tribal Health Consortium, both in the USA. 

They discuss the establishment of a network of population-based lupus patient registries in the USA and how these have been used to estimate the incidence rate of systemic lupus erythematosus using standardised data stratified by sex, race and ethnicity.

Access the article: https://lupus.bmj.com/content/8/1/e000614

Using patient registries to estimate SLE incidence rate in the USA

Duane Peters from the Lupus Foundation of America interviews Dr Gary Gilkeson from the Medical University of South Carolina about a phase I trial into the use of mesenchymal stromal cells (MSC) in refractory lupus patients in the USA, following impressive results of clinical improvement resulting from this therapy in China. 
The trial indicated that infusions of MSCs derived from the umbilical cord are safe and may be effective in treating mild to moderate systemic lupus erythematosus, with minimal adverse effects. 
Access the article: http://dx.doi.org/10.1136/lupus-2022-000704

Mesenchymal stromal cells: a potential new SLE treatment option?

Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: http://dx.doi.org/10.1136/lupus-2022-000763

Biomarker reduction indicates treatment response to Belimumab

ÑÅË¼·ÖÊÖ´óÊ¦

Notes du podcast: http://sesentirbien.coach/podcast/73/
LA communauté:  http://sesentirbien.coach/communaute/

Safety profile of anifrolumab in SLE patients

BMJ talk medicine

Related tracks